MenuClose
Attachment Large Size Large Wp Image 541

Discover the beauty of life once again

SWC now offering medical weight loss treatment

person looking in mirror after receiving medical weight loss treatment

Size Medium Wp Image 2866 AlignrightSpringfield Wellness Center, the first healthcare provider to bring intravenous NAD (nicotinamide adenine dinucleotide) to the United States, is now offering medical weight loss treatments with prescription products tailored to your needs, including the newer injectable medications, semaglutide and tirzepatide. Both medications were developed to control diabetes, but have been found effective at helping patients lose weight, as well.

What is semaglutide?

Semaglutide is an antihyperglycemic, Glucagon-Like Peptide-1 (GLP-1) receptor agonist originally developed to manage high blood sugar in people with Type 2 diabetes but also found to be effective at helping patients lose weight. Sold under the brand names Ozempic and Wegovy, the drug is administered by subcutaneous injection. It works by increasing the production of insulin, reducing hunger and food cravings, slowing digestion, and reducing body fat.

Studies conducted by the manufacturer over 68 weeks show that, on average, adults using semaglutide lost about 35 pounds, or about 15% of their body weight. In contrast, 31% of people using a placebo lost about 6 pounds, or about 2.5% of their body weight.

What is tirzepatide?

Tirzepatide (sold under the brand name Mounjaro) was also developed originally to treat Type 2 diabetes. Like semaglutide, tirzepatide is a GIP/GLP-1 receptor agonist, which means it works by increasing insulin production, decreasing blood sugar levels, slowing the rate at which food is digested (keeping you feeling full longer), and aiding weight loss. Though not currently FDA-approved for weight loss, tirzepatide has received FDA Fast-Track designation to speed its FDA application for treating adults with obesity, or who are overweight with weight-related health conditions. In one clinical trial (the SURMOUNT-1 trial), the average weight loss with tirzepatide after 72 weeks was 15% for the 5mg dose, 19.5% for the 10mg dose, and 20.9% for the 15mg dose.

Weight loss treatment at Springfield Wellness Center

We will evaluate and treat weight-loss patients every other Saturday, beginning Sept. 30. The treatment will be under the direction of Dr. Suzanne Parke, who is on the clinic’s medical staff and has been providing medical weight-loss support for patients for more than 20 years.

Springfield Wellness Center is located at 32872 Cullom Road, Springfield, LA 70462.

For more information, or to schedule an appointment, call 844.334.4727